Frazier Healthcare Partners
Frazier Healthcare Partners is a healthcare investment firm for pharmaceuticals, healthcare services, &a; medical products.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Frazier Healthcare Partners Information
Geographic Data
Address: 601 Union Street
City: Seattle
State: WA
Zip: 98101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$6B
Social
Twitter
Linkedin
Crunchbase
Metrics
2,885,569Website Global Rank
5,860Website Monthly Traffic
Twitter Followers
Description
Founded in 1991, Frazier Healthcare Partners is a leading provider of growth capital to healthcare companies. The firm has over $2B under management and has made investments in over 170 healthcare companies, with investment types ranging from company creation and venture capital to growth buyouts and leveraged recapitalizations. Frazier’s experienced team takes an active approach to helping build portfolio companies, leveraging the team’s deep domain expertise and expansive network of healthcare executives, advisors, and industry thought leaders. The firm’s Growth Buyout team invests in profitable companies focusing on healthcare services, pharmaceutical services, medical products, and related sectors. The firm’s Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Contact Phone:
+12066217200
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2018 | ARMO BioSciences | Venture Round | - |
| 8/2015 | Calibrium | Convertible Note | 1.7M |
| 1/2013 | Scilex Holding Company | Venture Round | - |
| 1/2014 | PowerVision | Series D | 0 |
| 3/2021 | Amunix | Series B | 117M |
| 1/2022 | Metagenomi | Series B | 0 |
| 1/2002 | QuatRx Pharmaceuticals | Series B | 2M |
| 4/2016 | Entasis Therapeutics | Series B | 50M |
| 1/2006 | Primaeva Medical | Series A | 1.3M |
| 4/2008 | Nuon Therapeutics | Series B | 27M |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 1/1996 | Corixa | Venture Round | - |
| 5/2019 | Phathom Pharmaceuticals | Private Equity Round | 90M |
| 1/2008 | Ascension Orthopedics | Series D | 21M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 12/2007 | Cardiac Dimensions | Series D | 0 |
| 12/2006 | Primaeva Medical | Series B | 7M |
| 8/2007 | FlowCardia | Series C | 0 |
| 12/2004 | QuatRx Pharmaceuticals | Series D | 15M |
| 1/2005 | PowerVision | Series A | 4.4M |
| 6/2006 | PatientKeeper | Series E | 0 |
| 11/2011 | Allena Pharmaceuticals | Series A | 15M |
| 12/2014 | Allena Pharmaceuticals | Series B | 0 |
| 1/2020 | REGENXBIO | Post-IPO Equity | - |
| 5/2011 | Silvergate Pharmaceuticals | Venture Round | 23.6M |
| 4/2012 | Alcresta | Series A | 10M |
| 3/2007 | Stromedix | Series A | 1M |
| 6/2017 | Alteon Health | Private Equity Round | - |
| 3/2016 | Iterum Therapeutics plc | Series A | 40M |
| 12/2020 | Rocket Pharmaceuticals | Post-IPO Equity | 299M |
| 1/2021 | Aclaris Therapeutics | Post-IPO Equity | - |
| 12/2007 | Pivot Medical | Series B | 0 |
| 7/2002 | Barosense | Series A | 6.2M |
| 1/1993 | VIVUS | Venture Round | - |
| 1/1991 | CV Therapeutics | Funding Round | - |
| 3/2020 | Molecular Templates | Post-IPO Debt | 45M |
| 3/2007 | Calistoga Pharmaceuticals | Series A | 21M |
| 8/2021 | Immunovant | Corporate Round | 200M |
| 6/2020 | Lassen Therapeutics | Series A | 31M |
| 12/2015 | Allena Pharmaceuticals | Series C | 0 |
| 11/2007 | Zonare Medical Systems | Series G | 30M |
| 8/2010 | Nuon Therapeutics | Venture Round | 10M |
| 11/2006 | Bariatric Partners | Series B | 0 |
| 1/2000 | ZymoGenetics | Funding Round | - |
| 3/2010 | Nuon Therapeutics | Venture Round | 6M |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 5/2007 | Arete Therapeutics | Series A | 35M |
| 9/2020 | Trillium Therapeutics | Post-IPO Equity | 25M |
| 12/2009 | EBR Systems | Venture Round | 15M |
| 2/2012 | Collegium Pharmaceutical | Venture Round | 22.5M |
| 8/2013 | Semnur Pharmaceuticals | Venture Round | 6M |
| 6/2010 | Calistoga Pharmaceuticals | Series C | 40M |
| 5/2016 | Aptinyx | Series A | 0 |
| 1/2006 | Xoft | Series C | 0 |
| 7/2010 | BARRX Medical | Series D | 15M |
| 9/2021 | Alpine Immune Sciences | Private Placement | 91M |
| 1/2019 | Alpine Immune Sciences | Post-IPO Equity | 25M |
| 10/2020 | Scholar Rock | Post-IPO Debt | 50M |
| 8/2005 | Cerexa Inc. | Series A | 0 |
| 1/2020 | Tarsus Pharmaceuticals | Series B | 60M |
| 12/2004 | Barosense | Series B | 6.2M |
| 3/2016 | Zavante Therapeutics | Series A | 45M |
| 1/2021 | Avadel Pharmaceuticals | Post-IPO Equity | - |
| 3/2013 | AcertaPharma | Series A | 60M |
| 1/1998 | Array BioPharma | Venture Round | - |
| 4/2020 | Dascena | Series B | 50M |
| 2/2000 | PatientKeeper | Series A | 8.6M |
| 10/2005 | EBR Systems | Series B | 21M |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 14M |
| 2/2011 | Chimerix | Series F | 45M |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 1/2020 | Epizyme | Post-IPO Equity | - |
| 1/2017 | The CORE Institute | Private Equity Round | - |
| 1/2000 | Simpata Inc | Series B | 20M |
| 7/2008 | Collegium Pharmaceutical | Series D | 0 |
| 2/2000 | Xenoport | Series A | 15.9M |
| 3/2007 | VentiRx Pharmaceuticals | Series A | 26.6M |
| 3/2013 | Achaogen | Series D | 18.9M |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 1/1991 | Tularik | Funding Round | - |
| 9/2010 | Tobira Therapeutics | Series B | 31M |
| 10/2007 | Zeltiq Aesthetics | Series B | 20.3M |
| 7/2011 | PowerVision | Series C | 24M |
| 2/2019 | Recida Therapeutics | Series A | 8.5M |
| 1/2020 | IVERIC bio | Post-IPO Equity | - |
| 5/2007 | CVRx | Series D | 65M |
| 1/1996 | ViroPharma | Funding Round | - |
| 5/2009 | Calistoga Pharmaceuticals | Series B | 30M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 9/2000 | Zonare Medical Systems | Series B | 9.5M |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 12/2020 | Sutro Biopharma | Post-IPO Equity | 144.9M |
| 11/2017 | Outpost Medicine, LLC | Series A | 20M |
| 12/2007 | Barosense | Series C | 11.2M |
| 11/2017 | Mavupharma | Series A | 0 |
| 11/2009 | Calibra Medical | Venture Round | 1.4M |
| 10/2007 | Altiris Therapeutics | Series B | 0 |
| 2/2009 | Primaeva Medical | Series C | 6M |
| 6/2004 | EBR Systems | Series A | 5.2M |
| 12/2017 | Aptinyx | Series B | 70M |
| 1/1997 | OraPharma Inc. (acquired by JNJ) | Venture Round | - |
| 4/2001 | Fast Track | Series C | 0 |
| 11/2022 | New Amsterdam Pharma | Post-IPO Equity | 0 |
| 3/2019 | Imago BioSciences | Series B | 40M |
| 8/2003 | Zonare Medical Systems | Series D | 6.5M |
| 11/2006 | Intradigm Corporation | Series A | 16M |
| 9/2014 | VentiRx Pharmaceuticals | Series B | 50.6M |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 11/2020 | Inipharm | Series A | 0 |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 10/2015 | Gritstone Bio | Series A | 102M |
| 10/2014 | Imago BioSciences | Series A | 26.5M |
| 11/2020 | Imago BioSciences | Series C | 80M |
| 3/2019 | Scout Bio | Series B | 20M |
| 5/2003 | Quantum Dot | Series B | 1.5M |
| 4/2010 | Achaogen | Series C | 56M |
| 10/2021 | Radionetics Oncology | Private Equity Round | 30M |
| 12/2007 | PowerVision | Series B | 20M |
| 9/2002 | Alexza Pharmaceuticals | Series A | 0 |
| 11/2011 | Rempex Pharmaceuticals | Series B | 67.5M |
| 4/2020 | Aspen Neuroscience | Series A | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 42M |
| 9/2018 | Arcutis Biotherapeutics | Series B | 58M |
| 6/2010 | Zeltiq Aesthetics | Series D | 25M |
| 1/2014 | Ignyta | Debt Financing | 10M |
| 1/2020 | Galera Therapeutics | Venture Round | - |
| 6/2016 | Alpine Immune Sciences | Series A | 48M |
| 4/2014 | Sierra Oncology | Series D | 0 |
| 1/2012 | Kalidex Pharmaceuticals | Venture Round | 6.5M |
| 5/2007 | Pegasus Biologics | Series C | 20M |
| 6/2003 | QuatRx Pharmaceuticals | Series C | 11.4M |
| 7/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 15M |
| 6/2008 | EBR Systems | Series C | 35M |
| 3/2017 | Vaxcyte | Series B | 60M |
| 7/2008 | CVRx | Series E | 0 |
| 5/2007 | Marcadia Biotech | Series A | 15M |
| 1/2019 | Sojournix | Series C | 44M |
| 9/2019 | Passage Bio | Series B | 110M |
| 1/2012 | Moximed | Venture Round | 1.8M |
| 8/2008 | Glaukos | Series D | 35M |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 8/2008 | Calibra Medical | Series B | 35M |
| 8/2000 | PatientKeeper | Series B | 0 |
| 2/2007 | Chimerix | Series D | 23.1M |
| 3/2020 | Vaxcyte | Series D | 0 |
| 4/2017 | Cirius Therapeutics | Series A | 0 |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 6/2005 | Pegasus Biologics | Series B | 10M |
| 7/2020 | MBX Biosciences | Series A | 34.6M |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 11/2009 | Calypso Medical | Series E | 50M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 10/2009 | Threshold Pharmaceuticals | Post-IPO Equity | 35M |
| 9/2013 | PreCision Dermatology | Debt Financing | 67M |
| 8/2018 | Cirius Therapeutics | Series A | 9M |
| 6/2005 | Cierra | Funding Round | 21M |
| 10/2005 | QuatRx Pharmaceuticals | Series D | 17M |
| 5/2020 | Lengo Therapeutics | Series A | 15M |
| 10/2003 | Cotherix | Series C | 55M |
| 11/2007 | AnaptysBio | Series B | 0 |
| 3/2016 | Outpost Medicine | Series A | 41M |
| 1/2007 | Calypso Medical | Series D | 42.2M |
| 1/2010 | VentiRx Pharmaceuticals | Series A | 25M |
| 2/2015 | Laguna Pharmaceuticals | Series B | 30M |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 10/2019 | Arcutis Biotherapeutics | Series C | 94.5M |
| 9/2020 | Silverback Therapeutics | Series C | 85M |
| 3/2015 | Collegium Pharmaceutical | Private Equity Round | 0 |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 7/2013 | Alcresta | Series B | 10M |
| 6/2016 | Iovance Biotherapeutics | Equity | 100M |
| 7/2015 | AnaptysBio | Series D | 40M |
| 8/2009 | Barosense | Series D | 27M |
| 7/2004 | Zonare Medical Systems | Series E | 34M |
| 1/2009 | Intradigm Corporation | Series B | 0 |
| 4/2007 | Xoft | Series D | 0 |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 6/2003 | Xoft | Series B | 0 |
| 5/2007 | Portola Pharmaceuticals | Series C | 70M |
| 4/2003 | Rigel Pharmaceuticals | Post-IPO Equity | 46M |
| 3/2020 | Amunix | Series A | 0 |
| 5/2005 | Xoft | Series C | 0 |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 3/2004 | Cardiac Dimensions | Series C | 15M |
| 8/2008 | PatientKeeper | Series F | 0 |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 3/2000 | MEDCHANNEL | Series B | 42M |
| 2/2019 | Passage Bio | Series A | 115.5M |
| 2/2013 | Glaukos | Series F | 30M |
| 2/2011 | Glaukos | Series E | 0 |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 6/2004 | PatientKeeper | Series D | 0 |
| 1/2005 | Alexza Pharmaceuticals | Series D | 0 |
| 2/2008 | Zonare Medical Systems | Equity | 30M |
| 4/2008 | Stromedix | Series B | 25M |
| 5/2009 | Clovis Oncology | Venture Round | 145M |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 5/2021 | Hummingbird Bioscience | Series C | 0 |
| 1/2023 | Curve Beam | Funding Round | 0 |
| 10/2008 | Alnara Pharmaceuticals | Series A | 20M |
| 3/2006 | PowerVision | Series A | 2M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 9/2021 | HilleVax | Equity | 135M |
| 2/2021 | Seraxis | Series C | 40M |
| 1/2007 | Calixa Therapeutics | Funding Round | - |
| 2/2007 | Pivot Medical | Series A | 2M |
| 1/2020 | Bellus Health | Post-IPO Equity | - |
| 3/2006 | Zeltiq Aesthetics | Series A | 7.5M |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 2/2021 | ESSA Pharma | Post-IPO Equity | 130M |
| 6/2010 | Incline Therapeutics | Series A | 43M |
| 12/2003 | FlowCardia | Series B | 12M |
| 8/2007 | Tobira Therapeutics | Series A | 31M |
| 3/2009 | Stemgent | Series B | 14M |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 20M |
| 8/2018 | Krystal Biotech | Post-IPO Equity | 10M |
| 4/2017 | Arcutis Biotherapeutics | Series A | 13.5M |
| 9/2002 | Glaukos | Series A | 10M |
| 1/2022 | Metagenomi | Series B | 0 |
| 12/2021 | Pardes Biosciences | Post-IPO Equity | 0 |
| 11/2021 | SanReno Therapeutics | Funding Round | 0 |
| 11/2021 | Tricida | Post-IPO Equity | 0 |
| 11/2021 | Silence Therapeutics | Post-IPO Equity | 0 |
| 10/2021 | Scout Bio | Series B | 0 |
| 10/2021 | Radionetics Oncology | Private Equity Round | 0 |
| 9/2021 | Gritstone Bio | Post-IPO Equity | 0 |
| 9/2021 | Alpine Immune Sciences | Post-IPO Equity | 0 |
| 9/2021 | HilleVax | Venture Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
